Lihui Wang

13PUBLICATIONS

19CO-AUTHORS

Molecular medicineMolecular targetsBiologically active moleculesCheminformatics and quantitative structure-activity relationships

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 29, 2026

4-Arylindolines Bearing a Pyrido[3,2-<i>d</i>]pyrimidine Scaffold as Dual Inhibitors of the PD-1/PD-L1 Interaction and NAMPT for Targeting Tumor Immunoevasion and Metabolism.

|Feb 04, 2026

Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.

Shougeng Liu, Yiting Jiang, Yudong Fu

|Nov 28, 2025

Novel Isoidide Subunit-Containing Xanthine Oxidase Inhibitors with Potent Hypouricemic Effects.

Xiaoyi Zeng, Yu Chen, Bing Xu

|Sep 30, 2025

Activation of epigenetic reprogramming via crotonylation overcomes resistance to EGFR-TKI therapy in lung cancer.

Sihong Chen, Mengyan Zhong, Xiaoyuan Wang

|Sep 17, 2025

Discovery of Pyrazole-Containing 4‑Arylindolines as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.

Wensong Deng, Yuan Yang, Tairen Zhou

|Nov 08, 2024

Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR-Mutant Non-Small Cell Lung Cancer.

Simeng Wang, Jia-Cheng Lai, Yu Li

Pageof 3

Frequent Collaborators

Mingze Qin

Yongshan Zhao

Jingyu Yang

Simeng Wang

Jiayu Zhang

Xin Zhai

Guoliang Chen

Jing Tang

Hongrui Lei

Xin Zhai

Frequent Collaborators

Mingze Qin

Yongshan Zhao

Jingyu Yang

Simeng Wang